[go: up one dir, main page]

NZ542476A - 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound - Google Patents

2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound

Info

Publication number
NZ542476A
NZ542476A NZ542476A NZ54247604A NZ542476A NZ 542476 A NZ542476 A NZ 542476A NZ 542476 A NZ542476 A NZ 542476A NZ 54247604 A NZ54247604 A NZ 54247604A NZ 542476 A NZ542476 A NZ 542476A
Authority
NZ
New Zealand
Prior art keywords
methoxypyridin
butyl
propyl
sulfonylamino
benzamide
Prior art date
Application number
NZ542476A
Other languages
English (en)
Inventor
Joachim Brendel
Heinz Goegelein
Klaus Wirth
Gert Ulrich Kuerzel
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NZ542476A publication Critical patent/NZ542476A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
NZ542476A 2003-03-18 2004-03-05 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound NZ542476A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10312073A DE10312073A1 (de) 2003-03-18 2003-03-18 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3yl)-propyl]-benzamid, dessen Verwendung als Medikament sowie dieses enthaltende pharmazeutische Zubereitungen
PCT/EP2004/002247 WO2004083157A1 (de) 2003-03-18 2004-03-05 2-(butyl-1-sulfonylamino)-n-[1(r)-(6-methoxy-pyridin-3-yl)-propyl]-benzamid, dessen verwendung als medikament sowie dieses enthaltende pharmazeutische zubereitungen

Publications (1)

Publication Number Publication Date
NZ542476A true NZ542476A (en) 2008-05-30

Family

ID=32920928

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ542476A NZ542476A (en) 2003-03-18 2004-03-05 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound

Country Status (22)

Country Link
EP (1) EP1606237A1 (es)
JP (1) JP2006520343A (es)
KR (1) KR20050110681A (es)
CN (1) CN100361943C (es)
AR (1) AR043622A1 (es)
AU (1) AU2004222137A1 (es)
BR (1) BRPI0408441A (es)
CA (1) CA2519022A1 (es)
DE (1) DE10312073A1 (es)
HK (1) HK1086819A1 (es)
HR (1) HRP20050815A2 (es)
MA (1) MA27749A1 (es)
MX (1) MXPA05009763A (es)
MY (1) MY176510A (es)
NO (1) NO20054472L (es)
NZ (1) NZ542476A (es)
PE (1) PE20050307A1 (es)
RS (1) RS20050690A (es)
RU (1) RU2333202C2 (es)
TW (1) TW200500342A (es)
WO (1) WO2004083157A1 (es)
ZA (1) ZA200506328B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004009931A1 (de) * 2004-02-26 2005-09-15 Aventis Pharma Deutschland Gmbh Kv1.5-Blocker zur selektiven Steigerung der Vorhofkontraktilität und Behandlung der Herzinsuffizienz
US7569589B2 (en) 2004-07-29 2009-08-04 Merck & Co., Inc. Potassium channel inhibitors
DE102005028845A1 (de) * 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
JP4943429B2 (ja) * 2005-07-22 2012-05-30 メルク・シャープ・エンド・ドーム・コーポレイション カリウムチャネル阻害剤
KR101605061B1 (ko) * 2009-05-29 2016-03-21 라퀄리아 파마 인코포레이티드 칼슘 또는 나트륨 채널 차단제로서의 아릴 치환된 카복사미드 유도체

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen

Also Published As

Publication number Publication date
CN1756728A (zh) 2006-04-05
MXPA05009763A (es) 2006-01-27
EP1606237A1 (de) 2005-12-21
PE20050307A1 (es) 2005-06-08
HK1086819A1 (en) 2006-09-29
BRPI0408441A (pt) 2006-04-04
AU2004222137A1 (en) 2004-09-30
RU2005132163A (ru) 2006-04-10
NO20054472L (no) 2005-09-27
AR043622A1 (es) 2005-08-03
HRP20050815A2 (en) 2006-09-30
MY176510A (en) 2020-08-12
CN100361943C (zh) 2008-01-16
JP2006520343A (ja) 2006-09-07
DE10312073A1 (de) 2004-09-30
KR20050110681A (ko) 2005-11-23
RS20050690A (sr) 2008-04-04
MA27749A1 (fr) 2006-02-01
CA2519022A1 (en) 2004-09-30
TW200500342A (en) 2005-01-01
RU2333202C2 (ru) 2008-09-10
WO2004083157A1 (de) 2004-09-30
ZA200506328B (en) 2006-04-26

Similar Documents

Publication Publication Date Title
JP4231295B2 (ja) アントラニル酸アミド、その製造方法、抗不整脈剤としてのその使用、およびその医薬調製物
JP4445198B2 (ja) カリウムチャンネルインヒビターとして使用するためのオルソ置換含窒素ビスアリール化合物
JP4051283B2 (ja) オルト−置換およびメタ−置換ビスアリール化合物、その製造法、医薬としてのその使用、並びにそれを含有する医薬製剤
KR20040030668A (ko) 헤테로아릴설포닐 측쇄를 갖는 안트라닐산 아미드, 이의제조방법, 약제 또는 진단제로서의 이의 용도 및 당해화합물을 함유하는 약제학적 제제
MX2011012559A (es) Moduladores de lxr.
US20020193422A1 (en) Anthranilamides and methods of their use
NZ542476A (en) 2-(Butyl-1-sulfonylamino)-N-[1(R)-(6-methoxy-pyridin-3-yl)-propyl]-benzamide, the use thereof in the form of drug and pharmaceutical preparations containing said compound
US20080081926A1 (en) Sulfonylaminobenzoic acid and salt
JP7032323B2 (ja) N-ホルミルペプチド受容体モジュレーターとしてのフェニル尿素誘導体
US8106099B2 (en) Combination of phenylcarboxamides with blockers of the IKr channel and their use for the treatment of atrial arrhythmias
US20050054673A1 (en) Combination of phenylcarboxylic acid amides with beta-adrenoreceptor blockers and their use for the treatment of atrial arrhythmias
JP4658919B2 (ja) フェニルカルボン酸アミドおよびIKrチャンネル遮断剤の組み合わせならびに心房性不整脈を処置するためのその使用
AU2004271697A1 (en) Combination of phenylcarboxamides with beta-adrenergic receptor blockers and use thereof for the treatment of atrial arrhythmias
JP2003026677A (ja) 3−フェニル−3,7−ジアザビシクロ[3,3,1]ノナン−化合物、これを含有する医薬品、その使用及びその製法
CN116023336A (zh) 一种具有Nav1.7钠离子通道靶向抑制作用的化合物及其药物组合物和用途
JP2003503478A (ja) 神経学的疾患の治療のためのβ−アミノ酸誘導体

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed